Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Zhu, C; Boucheron, N; Al-Rubaye, O; Chung, BK; Thorbjørnsen, LW; Köcher, T; Schuster, M; Claudel, T; Halilbasic, E; Kunczer, V; Muscate, F; Cavanagh, LL; Waltenberger, D; Lercher, A; Ohradanova-Repic, A; Schatzlmaier, P; Stojakovic, T; Scharnagl, H; Bergthaler, A; Stockinger, H; Huber, S; Bock, C; Kenner, L; Karlsen, TH; Ellmeier, W; Trauner, M.
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting TH17 pathogenicity and transdifferentiation.
Gut. 2025; Doi: 10.1136/gutjnl-2024-333297
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Trauner Michael
Co-Autor*innen der Med Uni Graz
Claudel Thierry
Halilbasic Emina
Scharnagl Hubert
Stojakovic Tatjana
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
BACKGROUND: 24-Nor-ursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid for treating immune-mediated cholestatic liver diseases, such as primary sclerosing cholangitis (PSC). OBJECTIVE: Since PSC strongly associates with T helper-type-like 17 (TH17)-mediated intestinal inflammation, we explored NorUDCA's immunomodulatory potential on TH17 cells. DESIGN: NorUDCA's impact on TH17 differentiation was assessed using a CD4+TNaive adoptive transfer mouse model, and on intraepithelial TH17 pathogenicity and transdifferentiation using an αCD3 stimulation model combined with interleukin-17A-fate-mapping. Mechanistic studies used molecular and multiomics approaches, flow cytometry and metabolic assays with pathogenic (p) TH17. Pathogenicity of pTH17 exposed to NorUDCA in vitro was evaluated following adoptive transfer in intestinal tissues or the central nervous system (CNS). Key findings were validated in an αCD3-stimulated humanised NSG mouse model reconstituted with peripheral blood mononuclear cells from patients with PSC. RESULTS: NorUDCA suppressed TH17 effector function and enriched regulatory T cell (Treg) abundance upon CD4+TNaive cell transfer. NorUDCA mitigated intraepithelial TH17 pathogenicity and decreased the generation of proinflammatory 'TH1-like-TH17' cells, and enhanced TH17 transdifferentiation into Treg and Tr1 (regulatory type 1) cells in the αCD3-model. In vivo ablation revealed that Treg induction is crucial for NorUDCA's anti-inflammatory effect on TH17 pathogenicity. Mechanistically, NorUDCA restrained pTH17 effector function and simultaneously promoted functional Treg formation in vitro, by attenuating a glutamine-mTORC1-glycolysis signalling axis. Exposure of pTH17 to NorUDCA dampened their pathogenicity and expansion in the intestine or CNS upon transfer. NorUDCA's impact on TH17 inflammation was corroborated in the humanised NSG mouse model. CONCLUSION: NorUDCA restricts TH17 inflammation in multiple mouse models, potentiating future clinical applications for treating TH17-mediated intestinal diseases and beyond.

Find related publications in this database (Keywords)
BILE ACID
PRIMARY SCLEROSING CHOLANGITIS
INFLAMMATORY BOWEL DISEASE
AUTOIMMUNE LIVER DISEASE
INTESTINAL T CELLS
© Med Uni Graz • Impressum